$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

$tgtx Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-K Financial Statement

#000114420416088155 Filed on March 15, 2016

Income Statement

Concept	2016 Q1	2015 Q4	2015 Q3
Revenue	$38.10K	$38.10K	$38.10K
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.410M	$2.420M	$2.290M
YoY Change	-51.99%	-33.15%	-39.58%
% of Gross Profit
Research & Development	$11.62M	$15.25M	$11.57M
YoY Change	20.8%	0.73%	-15.5%
% of Gross Profit
Depreciation & Amortization	$6.380K	$10.00K	$0.00
YoY Change	163.75%
% of Gross Profit
Operating Expenses	$14.03M	$17.68M	$13.86M
YoY Change	-4.17%	-5.76%	-20.68%
Operating Profit	-$13.99M		-$13.83M
YoY Change	-4.18%		-20.72%
Interest Expense	$242.4K	$30.00K	$246.5K
YoY Change	2.0%	-137.5%	5.0%
% of Operating Profit
Other Income/Expense, Net	$143.5K	$0.00	$0.00
YoY Change	471.33%		-100.0%
Pretax Income	-$13.85M	-$17.61M	-$13.66M
YoY Change	-5.01%	-6.33%	-21.72%
Income Tax
% Of Pretax Income
Net Earnings	-$13.85M	-$17.61M	-$13.66M
YoY Change	-5.0%	-6.3%	-21.75%
Net Earnings / Revenue	-36352.96%	-46231.3%	-35846.06%
Basic Earnings Per Share
Diluted Earnings Per Share	-$283.2K	-$365.7K	-$284.9K
COMMON SHARES
Basic Shares Outstanding	54.10M shares	52.52M shares	52.55M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q4	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.70M	$77.20M	$94.20M
YoY Change	-44.15%	-2.03%	40.18%
Cash & Equivalents	$6.800M	$55.06M	$5.600M
Short-Term Investments	$22.20M	$22.20M	$28.70M
Other Short-Term Assets	$11.70M	$308.3K	$457.9K
YoY Change	1566.99%	77.25%	76.99%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$70.60M	$86.87M	$104.7M
YoY Change	-39.0%	1.95%	36.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$300.0K	$47.12K	$69.23K
YoY Change	1108.65%	131.48%
Goodwill		$799.4K	$799.4K
YoY Change		0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$26.50M	$25.00M	$21.10M
YoY Change
Other Assets	$1.900M	$171.2K	$141.7K
YoY Change	1354.53%	24.86%	98.9%
Total Long-Term Assets	$29.50M	$26.60M	$22.68M
YoY Change	1826.96%	1636.44%	2618.53%
TOTAL ASSETS
Total Short-Term Assets	$70.60M	$86.87M	$104.7M
Total Long-Term Assets	$29.50M	$26.60M	$22.68M
Total Assets	$100.1M	$113.5M	$127.4M
YoY Change	-14.64%	30.81%	64.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.100M	$9.300M	$8.600M
YoY Change	-8.99%	132.5%	7.5%
Accrued Expenses	$400.0K	$800.0K	$800.0K
YoY Change	100.0%	14.29%	33.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$200.0K	$200.0K
YoY Change	-33.33%	-33.33%	0.0%
Total Short-Term Liabilities	$8.894M	$10.53M	$9.686M
YoY Change	-6.9%	105.59%	8.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.700M	$1.400M	$1.400M
YoY Change	13.33%	-6.67%	-12.5%
Total Long-Term Liabilities	$1.700M	$1.400M	$1.400M
YoY Change	13.33%	-6.67%	-12.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.894M	$10.53M	$9.686M
Total Long-Term Liabilities	$1.700M	$1.400M	$1.400M
Total Liabilities	$10.60M	$11.90M	$11.10M
YoY Change	-3.97%	79.08%	5.67%
SHAREHOLDERS EQUITY
Retained Earnings		-$158.1M	-$140.5M
YoY Change		66.13%	83.96%
Common Stock		$54.10K	$52.56K
YoY Change		20.28%	26.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$234.3K	$234.3K
YoY Change		0.0%	0.0%
Treasury Stock Shares	41.31K shares	41.31K shares
Shareholders Equity	$89.40M	$101.6M	$116.3M
YoY Change
Total Liabilities & Shareholders Equity	$100.1M	$113.5M	$127.4M
YoY Change	-14.64%	30.81%	64.3%

Cashflow Statement

Concept	2016 Q1	2015 Q4	2015 Q3
OPERATING ACTIVITIES
Net Income	-$13.85M	-$17.61M	-$13.66M
YoY Change	-5.0%	-6.3%	-21.75%
Depreciation, Depletion And Amortization	$6.380K	$10.00K	$0.00
YoY Change	163.75%
Cash From Operating Activities	-$16.67M	-$12.90M	-$10.66M
YoY Change	87.73%	-14.63%	32.42%
INVESTING ACTIVITIES
Capital Expenditures	$282.3K	$20.00K	-$40.00K
YoY Change	4000.84%	-200.0%
Acquisitions
YoY Change
Other Investing Activities	-$1.640M	$2.470M	$110.0K
YoY Change	-142.6%	-127.08%
Cash From Investing Activities	-$1.920M	$2.470M	$80.00K
YoY Change	-150.0%	-127.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	20.00K	15.74M
YoY Change	-99.97%	-99.93%	-34.96%
NET CHANGE
Cash From Operating Activities	-16.67M	-12.90M	-10.66M
Cash From Investing Activities	-1.920M	2.470M	80.00K
Cash From Financing Activities	10.00K	20.00K	15.74M
Net Change In Cash	-18.58M	-10.41M	5.160M
YoY Change	-161.34%	-521.46%	-68.05%
FREE CASH FLOW
Cash From Operating Activities	-$16.67M	-$12.90M	-$10.66M
Capital Expenditures	$282.3K	$20.00K	-$40.00K
Free Cash Flow	-$16.95M	-$12.92M	-$10.62M
YoY Change	90.76%	-14.38%	31.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Entity Registrant Name EntityRegistrantName	TG THERAPEUTICS, INC.
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001001316
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	570132000	USD
CY2015	dei	Trading Symbol TradingSymbol	TGTX
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54095110	shares
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55061329	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55713784	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	22166512	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	23062034	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47122	USD
CY2015Q4	us-gaap	Goodwill Goodwill	799391	USD
CY2014Q4	us-gaap	Goodwill Goodwill	799391	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	171182	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	137101	USD
CY2015Q4	us-gaap	Assets Assets	113473201	USD
CY2014Q4	us-gaap	Assets Assets	86746890	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9346068	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3991625	USD
CY2015Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	818472	USD
CY2014Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	702000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	152381	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	152381	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1371429	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1523810	USD
CY2015Q4	us-gaap	Liabilities Liabilities	11899899	USD
CY2014Q4	us-gaap	Liabilities Liabilities	6645006	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015	us-gaap	Other Income OtherIncome	0	USD
CY2014	us-gaap	Other Income OtherIncome	95427	USD
CY2015	us-gaap	Interest Income Other InterestIncomeOther	174653	USD
CY2013	us-gaap	Interest Expense InterestExpense	952888	USD
CY2015	tgtx	Change In Fair Value Of Non Current Note Payable ChangeInFairValueOfNonCurrentNotePayable	1029453	USD
CY2014	tgtx	Change In Fair Value Of Non Current Note Payable ChangeInFairValueOfNonCurrentNotePayable	720040	USD
CY2013	tgtx	Change In Fair Value Of Non Current Note Payable ChangeInFairValueOfNonCurrentNotePayable	3300951	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-60185	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2487779	USD
CY2013	us-gaap	Profit Loss ProfitLoss	-20478210	USD
CY2013	us-gaap	Depreciation Depreciation	1127	USD
CY2013	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	975	USD
CY2015Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	186021	USD
CY2014Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	85516	USD
CY2015Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	9151142	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	308327	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	86873331	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-158133926	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95185280	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	101573302	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80101884	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113473201	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86746890	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	54095	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	44974	USD
CY2015Q4	tgtx	Contingently Issuable Shares ContingentlyIssuableShares	6	USD
CY2014Q4	tgtx	Contingently Issuable Shares ContingentlyIssuableShares	6	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	259887464	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	175476521	USD
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	234337	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	234337	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	211549	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	579143	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	575012	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	25003032	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	275190	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10528470	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5121196	USD
CY2013	tgtx	Non Cash Stock Expense NonCashStockExpense	0	USD
CY2014	tgtx	Non Cash Stock Expense NonCashStockExpense	5350094	USD
CY2013	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	1041519	USD
CY2013	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	12621161	USD
CY2015	us-gaap	Licenses Revenue LicensesRevenue	152381	USD
CY2014	us-gaap	Licenses Revenue LicensesRevenue	152381	USD
CY2015	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	43445817	USD
CY2014	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	26004687	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47707223	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40086347	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13662680	USD
CY2015	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	11435686	USD
CY2014	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	12373726	USD
CY2013	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	4161629	USD
CY2015	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	4189488	USD
CY2014	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	3413400	USD
CY2013	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2496461	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15625174	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15787126	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6658090	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	63332397	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	55873473	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	23118370	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-63180016	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-55721092	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-22965989	USD
CY2014	us-gaap	Interest Income Other InterestIncomeOther	55049	USD
CY2013	us-gaap	Interest Income Other InterestIncomeOther	30822	USD
CY2013	us-gaap	Other Income OtherIncome	108894	USD
CY2015	us-gaap	Interest Expense InterestExpense	972736	USD
CY2014	us-gaap	Interest Expense InterestExpense	930701	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	231370	USD
CY2015	us-gaap	Profit Loss ProfitLoss	-62948646	USD
CY2014	us-gaap	Profit Loss ProfitLoss	-55781277	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.38
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.64
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45646414	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34068926	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25413964	shares
CY2014	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	95427	USD
CY2015	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	21105292	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	15697092	USD
CY2014	us-gaap	Depreciation Depreciation	3931	USD
CY2015	us-gaap	Depreciation Depreciation	15452	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10739110	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-18355289	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-24685869	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3556624	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1067339	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	677778	USD
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2014	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	65614260	USD
CY2014	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	193581	USD
CY2015	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	67760517	USD
CY2015	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	536142	USD
CY2014	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-210661	USD
CY2015	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	56717	USD
CY2014	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	4563067	USD
CY2015	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3105771	USD
CY2014	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	58347	USD
CY2015	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	100505	USD
CY2014	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-603377	USD
CY2015	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	5470915	USD
CY2014	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-94590	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-152381	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-152381	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-35059919	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-44690272	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18570	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42217	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	68643526	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	68723686	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	15228318	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-652455	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40485466	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	575012	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	4131	USD
CY2014	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	51980	USD
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	104170	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	41722	USD
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2015	tgtx	Proceeds From Maturities ProceedsFromMaturities	24350000	USD
CY2014	tgtx	Proceeds From Maturities ProceedsFromMaturities	0	USD
CY2015	tgtx	Shares Issued In Connection With In Licensing Agreement SharesIssuedInConnectionWithInLicensingAgreement	0	USD
CY2014	tgtx	Shares Issued In Connection With In Licensing Agreement SharesIssuedInConnectionWithInLicensingAgreement	5350094	USD
CY2015	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	48993652	USD
CY2014	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	18336719	USD
CY2015	tgtx	Reclassification Of Deferred Financing Costs ReclassificationOfDeferredFinancingCosts	-111810	USD
CY2014	tgtx	Reclassification Of Deferred Financing Costs ReclassificationOfDeferredFinancingCosts	0	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	202400	USD
CY2013	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	5203148	USD
CY2013	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	2414569	USD
CY2013	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-229258	USD
CY2013	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	27169	USD
CY2013	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	4034605	USD
CY2013	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	66506	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-152381	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5681	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4925552	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2280773	USD
CY2013	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2013	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	37648280	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	39694133	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	24029471	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16455995	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2013	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	85121	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2013	tgtx	Proceeds From Maturities ProceedsFromMaturities	0	USD
CY2013	tgtx	Shares Issued In Connection With In Licensing Agreement SharesIssuedInConnectionWithInLicensingAgreement	0	USD
CY2013	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	4919871	USD
CY2013	tgtx	Reclassification Of Deferred Financing Costs ReclassificationOfDeferredFinancingCosts	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	102400000	USD
CY2015Q4	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	600000	USD
CY2015Q4	tgtx	Prepaid Manufacturing PrepaidManufacturing	7700000	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10618584	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7064396	shares
CY2015Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	47169544	USD
CY2015	us-gaap	Held To Maturity Securities Unrecognized Holding Gains HeldToMaturitySecuritiesUnrecognizedHoldingGains	0	USD
CY2015	us-gaap	Held To Maturity Securities Unrecognized Holding Losses HeldToMaturitySecuritiesUnrecognizedHoldingLosses	108668	USD
CY2015Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	47060876	USD
CY2014Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	23062034	USD
CY2014	us-gaap	Held To Maturity Securities Unrecognized Holding Gains HeldToMaturitySecuritiesUnrecognizedHoldingGains	922	USD
CY2014	us-gaap	Held To Maturity Securities Unrecognized Holding Losses HeldToMaturitySecuritiesUnrecognizedHoldingLosses	5806	USD
CY2014Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	23057150	USD
CY2015Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	211549	USD
CY2015Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	211549	USD
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	275190	USD
CY2014Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	275190	USD
CY2015	tgtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings	972736	USD
CY2015	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-1029453	USD
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	211549	USD
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Available For Sale Securities Equity Securities AvailableForSaleSecuritiesEquitySecurities	250000000	USD
CY2015	tgtx	Stock Issued During Period Shares New Issues Shelf Registration Statement StockIssuedDuringPeriodSharesNewIssuesShelfRegistrationStatement	248000000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	22900000	USD
CY2015	tgtx	Additional Amount Receivable On Achievement Of Pre Specified Milestones AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones	5000000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41309	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41309	shares
CY2015	tgtx	Impairment Of In Process Research And Development ImpairmentOfInProcessResearchAndDevelopment	0	USD
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">CREDIT RISK</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and long-term investments. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">USE OF ESTIMATES</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54095110	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44974248	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54053801	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44932939	shares
CY2015	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	6924	USD
CY2014	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2015	tgtx	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	1067339	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	21105292	USD
CY2014	tgtx	Impairment Of In Process Research And Development ImpairmentOfInProcessResearchAndDevelopment	0	USD
CY2013	tgtx	Impairment Of In Process Research And Development ImpairmentOfInProcessResearchAndDevelopment	2797600	USD
CY2013	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2015	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2013	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	149799	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15550301	USD
CY2013	tgtx	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	2280773	USD
CY2013	tgtx	Stock Issued During Period Value Exercise Of Warrants Cash Less StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess	-1	USD
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5203148	USD
CY2013	tgtx	Treasury Stock Value During Peirod TreasuryStockValueDuringPeirod	-149799	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	40054492	USD
CY2014	tgtx	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3556624	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15697092	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	5350093	USD
CY2015	tgtx	Stock Issued During Period Value Exercise Of Warrants Cash Less StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess	0	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6925	USD
CY2014	tgtx	Issuance Of Common Stock In Connection With Exercise Of Options IssuanceOfCommonStockInConnectionWithExerciseOfOptions	202400	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2664970	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1344440	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1101572	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1310591	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8890796	shares
CY2013Q4	tgtx	Impairment Of In Process Research And Development ImpairmentOfInProcessResearchAndDevelopment	2797600	USD
CY2014	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.05	pure
CY2015	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.05	pure
CY2013Q3	tgtx	Stock Issued During Period Shares New Issues Over Allotments StockIssuedDuringPeriodSharesNewIssuesOverAllotments	855000	shares
CY2013Q3	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	37600000	USD
CY2015Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	8265583	USD
CY2014Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	12364537	USD
CY2015Q4	us-gaap	Cash Cash	46795746	USD
CY2014Q4	us-gaap	Cash Cash	43349247	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	64529	USD
CY2014	tgtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings	930701	USD
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-720040	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	275190	USD
CY2015	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	6924	USD
CY2013	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2797600	USD
CY2015Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1125
CY2012Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6781007	shares
CY2012Q4	tgtx	Warrant Or Right Outstanding Weighted Average Exercise Price WarrantOrRightOutstandingWeightedAverageExercisePrice	1.58
CY2012Q4	tgtx	Warrant Or Right Aggregate Intrinsic Value WarrantOrRightAggregateIntrinsicValue	14563539	USD
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5718947	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4148228	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1186749	shares
CY2013Q4	tgtx	Warrant Or Right Outstanding Weighted Average Exercise Price WarrantOrRightOutstandingWeightedAverageExercisePrice	1.34
CY2014Q4	tgtx	Warrant Or Right Outstanding Weighted Average Exercise Price WarrantOrRightOutstandingWeightedAverageExercisePrice	0.94
CY2015Q4	tgtx	Warrant Or Right Outstanding Weighted Average Exercise Price WarrantOrRightOutstandingWeightedAverageExercisePrice	2.37
CY2013Q4	tgtx	Warrant Or Right Aggregate Intrinsic Value WarrantOrRightAggregateIntrinsicValue	14809030	USD
CY2014Q4	tgtx	Warrant Or Right Aggregate Intrinsic Value WarrantOrRightAggregateIntrinsicValue	61792184	USD
CY2015Q4	tgtx	Warrant Or Right Aggregate Intrinsic Value WarrantOrRightAggregateIntrinsicValue	11341452	USD
CY2013	tgtx	Warrant Or Right Issued WarrantOrRightIssued	0	shares
CY2014	tgtx	Warrant Or Right Issued WarrantOrRightIssued	0	shares
CY2015	tgtx	Warrant Or Right Issued WarrantOrRightIssued	0	shares
CY2013	tgtx	Warrant Or Right Exercised WarrantOrRightExercised	1018068	shares
CY2014	tgtx	Warrant Or Right Exercised WarrantOrRightExercised	1560826	shares
CY2015	tgtx	Warrant Or Right Exercised WarrantOrRightExercised	2950115	shares
CY2013	tgtx	Warrant Or Right Exercised Weighted Average Exercise Price WarrantOrRightExercisedWeightedAverageExercisePrice	2.25
CY2014	tgtx	Warrant Or Right Exercised Weighted Average Exercise Price WarrantOrRightExercisedWeightedAverageExercisePrice	2.28
CY2015	tgtx	Warrant Or Right Exercised Weighted Average Exercise Price WarrantOrRightExercisedWeightedAverageExercisePrice	0.36
CY2013	tgtx	Warrant Or Right Expired WarrantOrRightExpired	43992	shares
CY2014	tgtx	Warrant Or Right Expired WarrantOrRightExpired	9893	shares
CY2015	tgtx	Warrant Or Right Expired WarrantOrRightExpired	11364	shares
CY2013	tgtx	Warrant Or Right Expired Weighted Average Exercise Price WarrantOrRightExpiredWeightedAverageExercisePrice	16.26
CY2014	tgtx	Warrant Or Right Expired Weighted Average Exercise Price WarrantOrRightExpiredWeightedAverageExercisePrice	20.74
CY2015	tgtx	Warrant Or Right Expired Weighted Average Exercise Price WarrantOrRightExpiredWeightedAverageExercisePrice	2.25
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15697092	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21105292	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5203148	USD
CY2013Q3	us-gaap	Share Price SharePrice	6.15
CY2013Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	35000000	USD
CY2013Q3	tgtx	Underwriting Discounts And Offering Expenses UnderwritingDiscountsAndOfferingExpenses	2700000	USD
CY2014	tgtx	Stock Issued During Period Value Issued For Cash1 StockIssuedDuringPeriodValueIssuedForCash1	50000000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48900000	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2015Q4	us-gaap	Notes Payable NotesPayable	211549	USD
CY2014Q4	us-gaap	Notes Payable NotesPayable	275190	USD
CY2010Q1	tgtx	Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt	0.5	pure
CY2011Q4	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.05	pure
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	68700379	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52350293	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4962298	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3358934	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	12087968	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	12417815	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	608205	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	956727	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	86358850	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	69083769	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	86358850	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	69083769	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	0	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-62948646	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-55781277	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20478210	USD
CY2015	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-21402540	USD
CY2014	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-18965634	USD
CY2013	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-6962592	USD
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-672306	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2533156	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-917810	USD
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1603364	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1092767	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	250000	USD
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	566310	USD
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	35459	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	43026	USD
CY2015	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	0	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-244814	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-1924558	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	5836819	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17275081	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	22800912	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10011934	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46283000	USD
CY2015	tgtx	Operating Loss Carry Forwards Expiration Period OperatingLossCarryForwardsExpirationPeriod	2035
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	1524000	USD
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	1676000	USD
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	1829000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	16335000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	128000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two And Three Years OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears	1947000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four And Five Years OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears	1992000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	12268000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	100000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	10000	USD
CY2015Q1	us-gaap	Clearing Fees Revenue ClearingFeesRevenue	38095	USD
CY2015Q2	us-gaap	Clearing Fees Revenue ClearingFeesRevenue	38095	USD
CY2015Q3	us-gaap	Clearing Fees Revenue ClearingFeesRevenue	38096	USD
CY2015Q4	us-gaap	Clearing Fees Revenue ClearingFeesRevenue	38095	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	14640946	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	17149675	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	13863680	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	17678096	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-14577735	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-17103183	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-13655916	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-17611812	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2014Q1	us-gaap	Clearing Fees Revenue ClearingFeesRevenue	38095	USD
CY2014Q2	us-gaap	Clearing Fees Revenue ClearingFeesRevenue	38095	USD
CY2014Q3	us-gaap	Clearing Fees Revenue ClearingFeesRevenue	38096	USD
CY2014Q4	us-gaap	Clearing Fees Revenue ClearingFeesRevenue	38095	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	7643220	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	11993592	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	17477442	USD
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	18759219	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-7547249	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-11986430	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-17451169	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-18796429	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.48
CY2015	tgtx	Stock Issued During Period Values Issued For Cash StockIssuedDuringPeriodValuesIssuedForCash	750005	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37648280	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16791408	USD
CY2015	tgtx	Stock Issued During Period Value Market Public Offering StockIssuedDuringPeriodValueMarketPublicOffering	66898703	USD
CY2014	tgtx	Stock Issued During Period Value Market Public Offering StockIssuedDuringPeriodValueMarketPublicOffering	48822852	USD
CY2015	tgtx	Stock Issued During Period Value Issued For Cash1 StockIssuedDuringPeriodValueIssuedForCash1	68200000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67000000	USD
CY2015	tgtx	Stock Issued During Period Shares Issued For Cash1 StockIssuedDuringPeriodSharesIssuedForCash1	4094498	shares
CY2014Q4	tgtx	Prepaid Manufacturing PrepaidManufacturing	5800000	USD

Files In Submission

Name	View Source	Status
0001144204-16-088155-index-headers.html	Edgar Link	pending
0001144204-16-088155-index.html	Edgar Link	pending
0001144204-16-088155.txt	Edgar Link	pending
0001144204-16-088155-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tgtx-20151231.xml	Edgar Link	completed
tgtx-20151231.xsd	Edgar Link	pending
tgtx-20151231_cal.xml	Edgar Link	unprocessable
tgtx-20151231_def.xml	Edgar Link	unprocessable
tgtx-20151231_lab.xml	Edgar Link	unprocessable
tgtx-20151231_pre.xml	Edgar Link	unprocessable
tpg10.jpg	Edgar Link	pending
tpg39.jpg	Edgar Link	pending
v432524_10k.htm	Edgar Link	pending
v432524_ex23-1.htm	Edgar Link	pending
v432524_ex31-1.htm	Edgar Link	pending
v432524_ex31-2.htm	Edgar Link	pending
v432524_ex32-1.htm	Edgar Link	pending
v432524_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

2016 Q1 Form 10-K Financial Statement

#000114420416088155 Filed on March 15, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX TG THERAPEUTICS, INC. Stock $tgtx

2016 Q1 Form 10-K Financial Statement

#000114420416088155 Filed on March 15, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx